Nuclear Medicine Program progress report for quarter ending September 30, 1988
During this period the properties of the unknown metabolite released from Langendorff-perfused rat hearts administered radioiodinated 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) have been further evaluated. Identification of this metabolite is important to provide a better understanding of the myocardial metabolism of methyl-branched fatty acids and to illuminate the factors affecting myocardial retention of such agents. The metabolite is the principal component in the outflow of the isolated rat hearts. Following isolation and purification of the metabolite, treatment with NaBH/sub 4/ had no effect on the chromatographic properties. In contrast, a much less polar product was formed by treatment with acetic anhydride, suggesting the presence of a primary or secondary hydroxyl group. In addition, the metabolite is soluble in dilute base and extracted from an acid solution with ether, demonstrating the presence of a carboxyl group. These combined results suggest BMIPP is metabolized to a hydroxy acid of unknown structure. Studies are now in progress to identify this material. Studies of the effects of chain length on the complexation of a series of p-carboxyalkylphenylglyoxal bis-(N-alkylthiosemicarbazones) (TSC) have continued. After complexation with either Cu-64 or Cu-67 followed by activation to the tetrafluorophenyl esters, the bifunctional ligands were attached to BSA and purified by G-25 Sephadex. Yields varied from 2--3% to 40%, with higher yields for the shorter chain analogues. Because of simpler formation and higher yield, future studies will focus on the radiolabeling of antibodies with the short-chain analogues of the 1,2-diketone TSC derivatives. Also during this period (I-131)IPPA was supplied to collaborators at the Institute of Clinical and Experimental Nuclear Medicine in Bonn, West Germany, for studies with an isolated working rat heart model.
- Research Organization:
- Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
- DOE Contract Number:
- AC05-84OR21400
- OSTI ID:
- 6151410
- Report Number(s):
- ORNL/TM-11043; ON: DE89009685
- Resource Relation:
- Other Information: Portions of this document are illegible in microfiche products
- Country of Publication:
- United States
- Language:
- English
Similar Records
Nuclear Medicine Program progress report for quarter ending September 30, 1989
Nuclear medicine progress report for quarter ending March 31, 1987
Related Subjects
59 BASIC BIOLOGICAL SCIENCES
MONOCARBOXYLIC ACIDS
IODINATION
RADIOPHARMACEUTICALS
SYNTHESIS
CHELATING AGENTS
COPPER 64
COPPER 67
HEART
IRIDIUM 192
LABELLED COMPOUNDS
METABOLITES
MONOCLONAL ANTIBODIES
NUCLEAR MEDICINE
ORNL
PROGRESS REPORT
PURIFICATION
RADIOBIOLOGY
RADIOCHEMISTRY
RATS
RHENIUM 186
RHENIUM 188
SALES
ANIMALS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BIOLOGY
BODY
CARBOXYLIC ACIDS
CARDIOVASCULAR SYSTEM
CHEMICAL REACTIONS
CHEMISTRY
COPPER ISOTOPES
DAYS LIVING RADIOISOTOPES
DOCUMENT TYPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
HALOGENATION
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
IRIDIUM ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MAMMALS
MEDICINE
MINUTES LIVING RADIOISOTOPES
NATIONAL ORGANIZATIONS
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANS
RADIOISOTOPES
RHENIUM ISOTOPES
RODENTS
US AEC
US DOE
US ERDA
US ORGANIZATIONS
VERTEBRATES
YEARS LIVING RADIOISOTOPES
550600* - Medicine
550500 - Metabolism